Skip to main content
. Author manuscript; available in PMC: 2008 Aug 22.
Published in final edited form as: Cell Death Differ. 2006 Apr 28;13(10):1697–1706. doi: 10.1038/sj.cdd.4401920

Figure 3.

Figure 3

Acridine orange (AO), TUNEL and anticleaved caspase-3 labelings. (a) Wild-type embryo (stage 13) labeled with AO. (b) Homozygous drICE17 mutant embryo (stage 13) labeled with AO. This embryo was obtained from a cross of homozygous drICE17 males and females to remove the maternal contribution. (c) Wild-type embryo (stage 13) labeled with TUNEL. (d) Homozygous drICE17 mutant embryo (stage 13) labeled for TUNEL. This embryo was obtained from a cross of homozygous drICE17 males and females to remove the maternal contribution. (e) Homozygous dcp-1Prev1 mutant embryo (stage 13) labeled for AO. This embryo was obtained from a cross of homozygous males and females to remove the maternal contribution. (f) dcp-1Prev1drICE17 double-mutant embryo (stage 13) labeled for AO. This embryo was obtained by induction of germline clones as described in Materials and Methods. (g) Wild-type embryo (stage 13) labeled with anticleaved caspase-3 antibody. (h) Homozygous drICE17 embryo (stage 13) labeled with anticleaved caspase-3 (Caspase-3*) antibody. The labeling pattern is not appreciately altered compared to wild-type (g). (i) Homozygous dcp-1Prev1 mutant embryo (stage 13) labeled with Caspase-3* antibody. This embryo was obtained from a cross of homozygous males and females to remove the maternal contribution